{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:09:41Z","timestamp":1790402981707,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["106-08"],"award-info":[{"award-number":["106-08"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jfma.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T09:41:11Z","timestamp":1593164471000},"page":"466-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"P2","title":["Impact of high plasma concentrations of linezolid in Taiwanese adult patients\u2014 therapeutic drug monitoring in improving adverse drug reactions"],"prefix":"10.1016","volume":"120","author":[{"given":"Chih-Ning","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Shiang","family":"Jhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-0850","authenticated-orcid":false,"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2020.06.011_bib1","first-page":"525","article-title":"A review of its use in the management of serious gram-positive infections Drugs","volume":"61","author":"Perry","year":"2001"},{"key":"10.1016\/j.jfma.2020.06.011_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jfma.2020.06.011_bib3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfma.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib5","first-page":"1189","article-title":"Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome Pharmacotherapy","volume":"27","author":"Narita","year":"2007"},{"key":"10.1016\/j.jfma.2020.06.011_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jfma.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jfma.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jfma.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Zamparini E and Furlanut M Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jfma.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.05.009","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients","volume":"48","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jfma.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2014.01.012","article-title":"Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight","volume":"79","author":"Niwa","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jfma.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jfma.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.06.011_bib17","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jfma.2020.06.011_bib18","series-title":"Guidance for industry: bioanalytical method validation, U.S. Department of Health and human services, food and drug administration, center for drug evaluation and research (CDER)","year":"2013"},{"key":"10.1016\/j.jfma.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2014.12.009","article-title":"Incidence and risk factors of linezolid-induced lactic acidosis","volume":"31","author":"Im","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jfma.2020.06.011_bib20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2169\/internalmedicine.50.4312","article-title":"Prediction of patient outcome from acinetobacter baumannii bacteremia with sequential organ failure assessment (SOFA) and acute physiology and chronic Health evaluation (apache) II scores","volume":"50","author":"Chen","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.jfma.2020.06.011_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jiac.2017.10.004","article-title":"Could qSOFA and SOFA score be correctly estimating the severity of healthcare-associated pneumonia?","volume":"24","author":"Asai","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib22","series-title":"IV injection , oral tablets, suspension","author":"Zyvox","year":"2015"},{"key":"10.1016\/j.jfma.2020.06.011_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.06.011_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00003246-200204000-00005","article-title":"Time course of platelet counts in critically ill patients","volume":"30","author":"Akca","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jfma.2020.06.011_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the aabb","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1086\/430441","article-title":"Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?","volume":"40","author":"Palenzuela","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccc.2010.12.013","article-title":"Lactate: biomarker and potential therapeutic target","volume":"27","author":"Okorie","year":"2011","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jfma.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.jfma.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s15010-007-6302-x","article-title":"Lactic acidosis after treatment with linezolid","volume":"35","author":"Wiener","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.jfma.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14740338.2017.1335305","article-title":"Piga D and Protti A Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes","volume":"16","author":"Santini","year":"2017","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.jfma.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfma.2020.06.011_bib32","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1124\/dmd.106.013755","article-title":"Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jfma.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620302400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620302400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:44:38Z","timestamp":1760539478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620302400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0929664620302400"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.06.011","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of high plasma concentrations of linezolid in Taiwanese adult patients\u2014 therapeutic drug monitoring in improving adverse drug reactions","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}